降压类药物临床应用经验汇总 !

2015-12-15 佚名 医学之声

高血压的现代治疗常用药物主要有五大类,即利尿剂、β受体阻滞剂、钙拮抗剂(CCB),血管紧张素转换酶抑制剂(ACEI)、血管紧张素Ⅱ受体拮抗剂(ARB)。另外我国也有一些复方制剂及中药制剂在使用。 1. 利尿药 氢氯噻嗪(噻嗪类利尿药) 12.5毫克/次  每日1~2次。 氯噻嗪(噻嗪类利尿药) 25~50毫克/次 每日1次。 螺内酯(噻嗪类利尿药)

高血压的现代治疗常用药物主要有五大类,即利尿剂、β受体阻滞剂、钙拮抗剂(CCB),血管紧张素转换酶抑制剂(ACEI)、血管紧张素Ⅱ受体拮抗剂(ARB)。另外我国也有一些复方制剂及中药制剂在使用。

1. 利尿药

氢氯噻嗪(噻嗪类利尿药)
12.5毫克/次  每日1~2次。

氯噻嗪(噻嗪类利尿药)
25~50毫克/次 每日1次。

螺内酯(噻嗪类利尿药)
20~40毫克/次  每日1~2次。

氨苯喋啶(潴钾利尿剂)
50毫克/次  每日1~2次

阿米洛利(潴钾利尿剂)
5~10毫克/次 每日1次

呋塞米(速尿)(袢利尿剂)
20~40毫克/次  每日1~2次

吲达帕胺(类似噻嗪利尿药)
1.25~2.5毫克/次 每日1次

特点:

降压起效较快,作用平稳,持续时间较长,且价格低廉。所以,尽管这些年有新的降压药物不断问世,但利尿剂仍然是高血压患者选用最多的的药物。服药2~3天后作用达高峰.适用于轻、中度高血压,对盐敏性高血压、合并肥胖,更年期女性和老年人有较强的降压效果。因能增强其他降压药的疗效而常和其他药物联合使用。长期使用应注意其对血脂、血糖、血尿酸的不良反应。.痛风者及肾功能不全者禁用.。

2.β受体阻滞剂

普萘洛尔(β阻滞剂)
10~20毫克/次 每日2~3次

美托洛尔(β阻滞剂)
25~50毫克/次 每日2次

阿替洛尔(β阻滞剂)
50~100毫克/次 每日1次

倍他洛尔(β阻滞剂)
10~20毫克/次 每日1次

比索洛尔(β阻滞剂)
5~10毫克/次 每日1次

卡维洛尔(α、β阻滞剂)
12.5~25毫克/次 每日1~2次

拉贝洛尔(α、β阻滞剂)
100毫克/次 每日2~3次

特点:

起效较迅速、强力,各药持续时间有差异.适用于各种不同严重程度高血压,特别是快心率的中青年患者、合并心绞痛患者,对老年高血压疗效较差.不良反应有心动过缓、乏力、四肢发冷.。有急性心力衰竭、支气管哮喘、病态窦房结综合征、房室传导阻滞、外周血管病者禁用。

3. 钙通道阻滞剂(CCB,钙拮抗剂)

硝苯地平(二氢吡啶类)
5~10毫克/次 每日3次

硝苯地平控释片(二氢吡啶类)
30~60毫克/次 每日1次

尼卡地平(二氢吡啶类)
40毫克/次 每日2次

尼群地平(二氢吡啶类)
10毫克/次 每日2次

非洛地平缓释剂(二氢吡啶类)
5~10毫克/次 每日1次

氨氯地平(二氢吡啶类)
5~10毫克/次 每日1次

拉西地平(二氢吡啶类)
4~6毫克/次 每日1次

乐卡地平(二氢吡啶类)
10~20毫克/次 每日1次

维拉帕米缓释剂(非二氢吡啶类)
240毫克/次 每日1次

地尔硫卓缓释剂(非二氢吡啶类)
90~180毫克/次 每日1次

特点:

起效迅速、强力,降压疗效和降压幅度较强,疗效与剂量成正比,疗效的个体差异较小,常与其他类型降压药联合治疗以增强作用。.除心力衰竭外较少有禁忌证.对老年患者降压效果较好。对嗜酒患者也有显著降压作用,可用于合并糖尿病、冠心病和外周血管病患者,长期使用有抗动脉粥样硬化作用。不良反应是引起心率增快、面部潮红、头痛、下肢水肿(服用利尿剂无效)。非二氢吡啶类药物对心力衰竭、窦房结功能低下、心传导阻滞者禁用。

4. 血管紧张素转换酶抑制剂(ACEI)

卡托普利(ACEI)
12.5~50毫克/次 每日2~3 次

依那普利(ACEI)
10~20毫克/次 每日2次

贝那普利(ACEI)
10~20毫克/次 每日1次

赖诺普利(ACEI)
10~20毫克/次 每日1次

雷米普利(ACEI)
2.5~10毫克/次 每日1次

福辛普利(ACEI)
10~20毫克/次 每日1次

西拉普利(ACEI)
2.5~5毫克/次 每日1次

培哚普利(ACEI)
4~8毫克/次 每日1次

特点:

起效缓慢、逐渐增强,在3~4周达最大作用,限制钠盐摄入或联合利尿剂可使起效迅速和作用增强,除可以降低血压外,还有保护新、脑、肾的作用。对肥胖、糖尿病和靶器官受损的高血压者具有较好的疗效,尤其适用于伴充血性心力衰竭、心肌梗死后、糖尿病患者。不良反应是有刺激性干咳(10---40%)和血管性水肿(罕见,但很严重)。高血钾症、妊娠和双侧肾动脉狭窄者禁用。血肌苷超过3毫克使用需谨慎。

5. 血管紧张素Ⅱ受体阻滞剂(ARB)

氯沙坦(ARB)
50~100毫克/次 每日1次。

缬沙坦(ARB)
80~160毫克/次 每日1次。

伊贝沙坦(ARB)
150~300毫克/次 每日1次。

替米沙坦(ARB)
40~80毫克/次 每日1次。

坎地沙坦(ARB)
8~16毫克/次 每日1次。

特点:

起效缓慢,但持久而平稳,在6~8周达最大作用,作用持续时间达24小时以上。.限制钠盐摄入或联合利尿剂可使疗效明显增强.治疗剂量窗较宽,疗效与剂量增大而作用增强。本类药是90年代末投放市场,价格昂贵,相关临床数据还较少,直接与药物有关的不良反应少,ARB的治疗对象和禁忌证与ACEI相同,是后者不良反应的替换药。

中医药治疗

按中医辨证分型进行,肝阳偏盛性治以平肝潜阳,用天麻钩藤饮加减,肝肾阴虚型治以育阴潜阳,用六味地黄汤加减,阴阳两虚型治以温阳育阴,用地黄饮子加减。在单方治疗方面,有一定降压效果的单位种药有野菊花、黄芩、杜仲、丹皮、黄连、川芎等,罗布麻、夏枯草兼有利尿作用。
  
降压药的联合应用

现有的临床试验结果支持以下类别降压药的组合:

1、利尿剂和β受体阻滞剂。
2、利尿剂和ACEI或ARB。
3、钙拮抗剂(二氢吡啶)和β受体阻滞剂。
4、钙拮抗剂和ACEI或ARB。
5、钙拮抗剂和利尿剂。
6、α受体阻滞剂和β受体阻滞剂。
7 、ACEI与ARB。

药物治疗的原则:

(1)采用较小的有效剂量以获得可能的疗效而使不良反应最小,如效果不满意,可逐步增加剂量以获得最佳疗效。

(2)为了有效地防止靶器官损害,要求每天24小时内血压稳定于目标范围内,最好使用一天一次给药而有持续24小时作用的药物。

(3)为使降压效果增大而不增加不良反应,可以采用两种或多种降压药联合应用。2级以上高血压为达到目标血压常需降压药联合应用。

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (16)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1835608, encodeId=eafb1835608a9, content=<a href='/topic/show?id=cfdc22e893f' target=_blank style='color:#2F92EE;'>#临床应用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22789, encryptionId=cfdc22e893f, topicName=临床应用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fc8528, createdName=clmlylxy, createdTime=Sat Sep 03 03:59:00 CST 2016, time=2016-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=55232, encodeId=b742552328c, content=谢谢分享,, beContent=null, objectType=article, channel=null, level=null, likeNumber=172, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Sat Jan 09 22:52:00 CST 2016, time=2016-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=55233, encodeId=c6fc5523379, content=已经收藏!, beContent=null, objectType=article, channel=null, level=null, likeNumber=197, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Sat Jan 09 22:52:00 CST 2016, time=2016-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=55229, encodeId=9c135522984, content=好,, beContent=null, objectType=article, channel=null, level=null, likeNumber=169, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Sat Jan 09 22:51:00 CST 2016, time=2016-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=55230, encodeId=684b55230e3, content=赞一个,, beContent=null, objectType=article, channel=null, level=null, likeNumber=133, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Sat Jan 09 22:51:00 CST 2016, time=2016-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=55231, encodeId=414f5523183, content=赞!, beContent=null, objectType=article, channel=null, level=null, likeNumber=195, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Sat Jan 09 22:51:00 CST 2016, time=2016-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=48354, encodeId=3ebf4835400, content=好文章,值得看。, beContent=null, objectType=article, channel=null, level=null, likeNumber=132, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bc301610909, createdName=hixiaoluo, createdTime=Sat Dec 26 16:34:00 CST 2015, time=2015-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=48355, encodeId=b3214835555, content=好文章,值得看。, beContent=null, objectType=article, channel=null, level=null, likeNumber=134, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bc301610909, createdName=hixiaoluo, createdTime=Sat Dec 26 16:34:00 CST 2015, time=2015-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=48356, encodeId=c54f48356a0, content=好文章,值得看。, beContent=null, objectType=article, channel=null, level=null, likeNumber=134, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bc301610909, createdName=hixiaoluo, createdTime=Sat Dec 26 16:34:00 CST 2015, time=2015-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=46687, encodeId=05984668e6a, content=太全面了!非常感谢!, beContent=null, objectType=article, channel=null, level=null, likeNumber=135, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=abdc1672404, createdName=lulu2h, createdTime=Sat Dec 19 00:40:00 CST 2015, time=2015-12-19, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1835608, encodeId=eafb1835608a9, content=<a href='/topic/show?id=cfdc22e893f' target=_blank style='color:#2F92EE;'>#临床应用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22789, encryptionId=cfdc22e893f, topicName=临床应用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fc8528, createdName=clmlylxy, createdTime=Sat Sep 03 03:59:00 CST 2016, time=2016-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=55232, encodeId=b742552328c, content=谢谢分享,, beContent=null, objectType=article, channel=null, level=null, likeNumber=172, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Sat Jan 09 22:52:00 CST 2016, time=2016-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=55233, encodeId=c6fc5523379, content=已经收藏!, beContent=null, objectType=article, channel=null, level=null, likeNumber=197, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Sat Jan 09 22:52:00 CST 2016, time=2016-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=55229, encodeId=9c135522984, content=好,, beContent=null, objectType=article, channel=null, level=null, likeNumber=169, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Sat Jan 09 22:51:00 CST 2016, time=2016-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=55230, encodeId=684b55230e3, content=赞一个,, beContent=null, objectType=article, channel=null, level=null, likeNumber=133, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Sat Jan 09 22:51:00 CST 2016, time=2016-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=55231, encodeId=414f5523183, content=赞!, beContent=null, objectType=article, channel=null, level=null, likeNumber=195, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Sat Jan 09 22:51:00 CST 2016, time=2016-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=48354, encodeId=3ebf4835400, content=好文章,值得看。, beContent=null, objectType=article, channel=null, level=null, likeNumber=132, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bc301610909, createdName=hixiaoluo, createdTime=Sat Dec 26 16:34:00 CST 2015, time=2015-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=48355, encodeId=b3214835555, content=好文章,值得看。, beContent=null, objectType=article, channel=null, level=null, likeNumber=134, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bc301610909, createdName=hixiaoluo, createdTime=Sat Dec 26 16:34:00 CST 2015, time=2015-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=48356, encodeId=c54f48356a0, content=好文章,值得看。, beContent=null, objectType=article, channel=null, level=null, likeNumber=134, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bc301610909, createdName=hixiaoluo, createdTime=Sat Dec 26 16:34:00 CST 2015, time=2015-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=46687, encodeId=05984668e6a, content=太全面了!非常感谢!, beContent=null, objectType=article, channel=null, level=null, likeNumber=135, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=abdc1672404, createdName=lulu2h, createdTime=Sat Dec 19 00:40:00 CST 2015, time=2015-12-19, status=1, ipAttribution=)]
    2016-01-09 medsic

    谢谢分享,

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1835608, encodeId=eafb1835608a9, content=<a href='/topic/show?id=cfdc22e893f' target=_blank style='color:#2F92EE;'>#临床应用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22789, encryptionId=cfdc22e893f, topicName=临床应用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fc8528, createdName=clmlylxy, createdTime=Sat Sep 03 03:59:00 CST 2016, time=2016-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=55232, encodeId=b742552328c, content=谢谢分享,, beContent=null, objectType=article, channel=null, level=null, likeNumber=172, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Sat Jan 09 22:52:00 CST 2016, time=2016-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=55233, encodeId=c6fc5523379, content=已经收藏!, beContent=null, objectType=article, channel=null, level=null, likeNumber=197, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Sat Jan 09 22:52:00 CST 2016, time=2016-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=55229, encodeId=9c135522984, content=好,, beContent=null, objectType=article, channel=null, level=null, likeNumber=169, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Sat Jan 09 22:51:00 CST 2016, time=2016-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=55230, encodeId=684b55230e3, content=赞一个,, beContent=null, objectType=article, channel=null, level=null, likeNumber=133, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Sat Jan 09 22:51:00 CST 2016, time=2016-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=55231, encodeId=414f5523183, content=赞!, beContent=null, objectType=article, channel=null, level=null, likeNumber=195, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Sat Jan 09 22:51:00 CST 2016, time=2016-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=48354, encodeId=3ebf4835400, content=好文章,值得看。, beContent=null, objectType=article, channel=null, level=null, likeNumber=132, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bc301610909, createdName=hixiaoluo, createdTime=Sat Dec 26 16:34:00 CST 2015, time=2015-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=48355, encodeId=b3214835555, content=好文章,值得看。, beContent=null, objectType=article, channel=null, level=null, likeNumber=134, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bc301610909, createdName=hixiaoluo, createdTime=Sat Dec 26 16:34:00 CST 2015, time=2015-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=48356, encodeId=c54f48356a0, content=好文章,值得看。, beContent=null, objectType=article, channel=null, level=null, likeNumber=134, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bc301610909, createdName=hixiaoluo, createdTime=Sat Dec 26 16:34:00 CST 2015, time=2015-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=46687, encodeId=05984668e6a, content=太全面了!非常感谢!, beContent=null, objectType=article, channel=null, level=null, likeNumber=135, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=abdc1672404, createdName=lulu2h, createdTime=Sat Dec 19 00:40:00 CST 2015, time=2015-12-19, status=1, ipAttribution=)]
    2016-01-09 medsic

    已经收藏!

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1835608, encodeId=eafb1835608a9, content=<a href='/topic/show?id=cfdc22e893f' target=_blank style='color:#2F92EE;'>#临床应用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22789, encryptionId=cfdc22e893f, topicName=临床应用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fc8528, createdName=clmlylxy, createdTime=Sat Sep 03 03:59:00 CST 2016, time=2016-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=55232, encodeId=b742552328c, content=谢谢分享,, beContent=null, objectType=article, channel=null, level=null, likeNumber=172, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Sat Jan 09 22:52:00 CST 2016, time=2016-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=55233, encodeId=c6fc5523379, content=已经收藏!, beContent=null, objectType=article, channel=null, level=null, likeNumber=197, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Sat Jan 09 22:52:00 CST 2016, time=2016-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=55229, encodeId=9c135522984, content=好,, beContent=null, objectType=article, channel=null, level=null, likeNumber=169, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Sat Jan 09 22:51:00 CST 2016, time=2016-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=55230, encodeId=684b55230e3, content=赞一个,, beContent=null, objectType=article, channel=null, level=null, likeNumber=133, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Sat Jan 09 22:51:00 CST 2016, time=2016-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=55231, encodeId=414f5523183, content=赞!, beContent=null, objectType=article, channel=null, level=null, likeNumber=195, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Sat Jan 09 22:51:00 CST 2016, time=2016-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=48354, encodeId=3ebf4835400, content=好文章,值得看。, beContent=null, objectType=article, channel=null, level=null, likeNumber=132, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bc301610909, createdName=hixiaoluo, createdTime=Sat Dec 26 16:34:00 CST 2015, time=2015-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=48355, encodeId=b3214835555, content=好文章,值得看。, beContent=null, objectType=article, channel=null, level=null, likeNumber=134, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bc301610909, createdName=hixiaoluo, createdTime=Sat Dec 26 16:34:00 CST 2015, time=2015-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=48356, encodeId=c54f48356a0, content=好文章,值得看。, beContent=null, objectType=article, channel=null, level=null, likeNumber=134, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bc301610909, createdName=hixiaoluo, createdTime=Sat Dec 26 16:34:00 CST 2015, time=2015-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=46687, encodeId=05984668e6a, content=太全面了!非常感谢!, beContent=null, objectType=article, channel=null, level=null, likeNumber=135, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=abdc1672404, createdName=lulu2h, createdTime=Sat Dec 19 00:40:00 CST 2015, time=2015-12-19, status=1, ipAttribution=)]
    2016-01-09 medsic

    好,

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1835608, encodeId=eafb1835608a9, content=<a href='/topic/show?id=cfdc22e893f' target=_blank style='color:#2F92EE;'>#临床应用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22789, encryptionId=cfdc22e893f, topicName=临床应用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fc8528, createdName=clmlylxy, createdTime=Sat Sep 03 03:59:00 CST 2016, time=2016-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=55232, encodeId=b742552328c, content=谢谢分享,, beContent=null, objectType=article, channel=null, level=null, likeNumber=172, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Sat Jan 09 22:52:00 CST 2016, time=2016-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=55233, encodeId=c6fc5523379, content=已经收藏!, beContent=null, objectType=article, channel=null, level=null, likeNumber=197, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Sat Jan 09 22:52:00 CST 2016, time=2016-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=55229, encodeId=9c135522984, content=好,, beContent=null, objectType=article, channel=null, level=null, likeNumber=169, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Sat Jan 09 22:51:00 CST 2016, time=2016-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=55230, encodeId=684b55230e3, content=赞一个,, beContent=null, objectType=article, channel=null, level=null, likeNumber=133, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Sat Jan 09 22:51:00 CST 2016, time=2016-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=55231, encodeId=414f5523183, content=赞!, beContent=null, objectType=article, channel=null, level=null, likeNumber=195, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Sat Jan 09 22:51:00 CST 2016, time=2016-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=48354, encodeId=3ebf4835400, content=好文章,值得看。, beContent=null, objectType=article, channel=null, level=null, likeNumber=132, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bc301610909, createdName=hixiaoluo, createdTime=Sat Dec 26 16:34:00 CST 2015, time=2015-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=48355, encodeId=b3214835555, content=好文章,值得看。, beContent=null, objectType=article, channel=null, level=null, likeNumber=134, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bc301610909, createdName=hixiaoluo, createdTime=Sat Dec 26 16:34:00 CST 2015, time=2015-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=48356, encodeId=c54f48356a0, content=好文章,值得看。, beContent=null, objectType=article, channel=null, level=null, likeNumber=134, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bc301610909, createdName=hixiaoluo, createdTime=Sat Dec 26 16:34:00 CST 2015, time=2015-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=46687, encodeId=05984668e6a, content=太全面了!非常感谢!, beContent=null, objectType=article, channel=null, level=null, likeNumber=135, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=abdc1672404, createdName=lulu2h, createdTime=Sat Dec 19 00:40:00 CST 2015, time=2015-12-19, status=1, ipAttribution=)]
    2016-01-09 medsic

    赞一个,

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1835608, encodeId=eafb1835608a9, content=<a href='/topic/show?id=cfdc22e893f' target=_blank style='color:#2F92EE;'>#临床应用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22789, encryptionId=cfdc22e893f, topicName=临床应用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fc8528, createdName=clmlylxy, createdTime=Sat Sep 03 03:59:00 CST 2016, time=2016-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=55232, encodeId=b742552328c, content=谢谢分享,, beContent=null, objectType=article, channel=null, level=null, likeNumber=172, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Sat Jan 09 22:52:00 CST 2016, time=2016-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=55233, encodeId=c6fc5523379, content=已经收藏!, beContent=null, objectType=article, channel=null, level=null, likeNumber=197, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Sat Jan 09 22:52:00 CST 2016, time=2016-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=55229, encodeId=9c135522984, content=好,, beContent=null, objectType=article, channel=null, level=null, likeNumber=169, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Sat Jan 09 22:51:00 CST 2016, time=2016-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=55230, encodeId=684b55230e3, content=赞一个,, beContent=null, objectType=article, channel=null, level=null, likeNumber=133, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Sat Jan 09 22:51:00 CST 2016, time=2016-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=55231, encodeId=414f5523183, content=赞!, beContent=null, objectType=article, channel=null, level=null, likeNumber=195, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Sat Jan 09 22:51:00 CST 2016, time=2016-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=48354, encodeId=3ebf4835400, content=好文章,值得看。, beContent=null, objectType=article, channel=null, level=null, likeNumber=132, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bc301610909, createdName=hixiaoluo, createdTime=Sat Dec 26 16:34:00 CST 2015, time=2015-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=48355, encodeId=b3214835555, content=好文章,值得看。, beContent=null, objectType=article, channel=null, level=null, likeNumber=134, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bc301610909, createdName=hixiaoluo, createdTime=Sat Dec 26 16:34:00 CST 2015, time=2015-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=48356, encodeId=c54f48356a0, content=好文章,值得看。, beContent=null, objectType=article, channel=null, level=null, likeNumber=134, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bc301610909, createdName=hixiaoluo, createdTime=Sat Dec 26 16:34:00 CST 2015, time=2015-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=46687, encodeId=05984668e6a, content=太全面了!非常感谢!, beContent=null, objectType=article, channel=null, level=null, likeNumber=135, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=abdc1672404, createdName=lulu2h, createdTime=Sat Dec 19 00:40:00 CST 2015, time=2015-12-19, status=1, ipAttribution=)]
    2016-01-09 medsic

    赞!

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=1835608, encodeId=eafb1835608a9, content=<a href='/topic/show?id=cfdc22e893f' target=_blank style='color:#2F92EE;'>#临床应用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22789, encryptionId=cfdc22e893f, topicName=临床应用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fc8528, createdName=clmlylxy, createdTime=Sat Sep 03 03:59:00 CST 2016, time=2016-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=55232, encodeId=b742552328c, content=谢谢分享,, beContent=null, objectType=article, channel=null, level=null, likeNumber=172, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Sat Jan 09 22:52:00 CST 2016, time=2016-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=55233, encodeId=c6fc5523379, content=已经收藏!, beContent=null, objectType=article, channel=null, level=null, likeNumber=197, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Sat Jan 09 22:52:00 CST 2016, time=2016-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=55229, encodeId=9c135522984, content=好,, beContent=null, objectType=article, channel=null, level=null, likeNumber=169, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Sat Jan 09 22:51:00 CST 2016, time=2016-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=55230, encodeId=684b55230e3, content=赞一个,, beContent=null, objectType=article, channel=null, level=null, likeNumber=133, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Sat Jan 09 22:51:00 CST 2016, time=2016-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=55231, encodeId=414f5523183, content=赞!, beContent=null, objectType=article, channel=null, level=null, likeNumber=195, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Sat Jan 09 22:51:00 CST 2016, time=2016-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=48354, encodeId=3ebf4835400, content=好文章,值得看。, beContent=null, objectType=article, channel=null, level=null, likeNumber=132, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bc301610909, createdName=hixiaoluo, createdTime=Sat Dec 26 16:34:00 CST 2015, time=2015-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=48355, encodeId=b3214835555, content=好文章,值得看。, beContent=null, objectType=article, channel=null, level=null, likeNumber=134, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bc301610909, createdName=hixiaoluo, createdTime=Sat Dec 26 16:34:00 CST 2015, time=2015-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=48356, encodeId=c54f48356a0, content=好文章,值得看。, beContent=null, objectType=article, channel=null, level=null, likeNumber=134, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bc301610909, createdName=hixiaoluo, createdTime=Sat Dec 26 16:34:00 CST 2015, time=2015-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=46687, encodeId=05984668e6a, content=太全面了!非常感谢!, beContent=null, objectType=article, channel=null, level=null, likeNumber=135, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=abdc1672404, createdName=lulu2h, createdTime=Sat Dec 19 00:40:00 CST 2015, time=2015-12-19, status=1, ipAttribution=)]
    2015-12-26 hixiaoluo

    好文章,值得看。

    0

  8. [GetPortalCommentsPageByObjectIdResponse(id=1835608, encodeId=eafb1835608a9, content=<a href='/topic/show?id=cfdc22e893f' target=_blank style='color:#2F92EE;'>#临床应用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22789, encryptionId=cfdc22e893f, topicName=临床应用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fc8528, createdName=clmlylxy, createdTime=Sat Sep 03 03:59:00 CST 2016, time=2016-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=55232, encodeId=b742552328c, content=谢谢分享,, beContent=null, objectType=article, channel=null, level=null, likeNumber=172, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Sat Jan 09 22:52:00 CST 2016, time=2016-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=55233, encodeId=c6fc5523379, content=已经收藏!, beContent=null, objectType=article, channel=null, level=null, likeNumber=197, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Sat Jan 09 22:52:00 CST 2016, time=2016-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=55229, encodeId=9c135522984, content=好,, beContent=null, objectType=article, channel=null, level=null, likeNumber=169, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Sat Jan 09 22:51:00 CST 2016, time=2016-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=55230, encodeId=684b55230e3, content=赞一个,, beContent=null, objectType=article, channel=null, level=null, likeNumber=133, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Sat Jan 09 22:51:00 CST 2016, time=2016-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=55231, encodeId=414f5523183, content=赞!, beContent=null, objectType=article, channel=null, level=null, likeNumber=195, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Sat Jan 09 22:51:00 CST 2016, time=2016-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=48354, encodeId=3ebf4835400, content=好文章,值得看。, beContent=null, objectType=article, channel=null, level=null, likeNumber=132, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bc301610909, createdName=hixiaoluo, createdTime=Sat Dec 26 16:34:00 CST 2015, time=2015-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=48355, encodeId=b3214835555, content=好文章,值得看。, beContent=null, objectType=article, channel=null, level=null, likeNumber=134, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bc301610909, createdName=hixiaoluo, createdTime=Sat Dec 26 16:34:00 CST 2015, time=2015-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=48356, encodeId=c54f48356a0, content=好文章,值得看。, beContent=null, objectType=article, channel=null, level=null, likeNumber=134, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bc301610909, createdName=hixiaoluo, createdTime=Sat Dec 26 16:34:00 CST 2015, time=2015-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=46687, encodeId=05984668e6a, content=太全面了!非常感谢!, beContent=null, objectType=article, channel=null, level=null, likeNumber=135, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=abdc1672404, createdName=lulu2h, createdTime=Sat Dec 19 00:40:00 CST 2015, time=2015-12-19, status=1, ipAttribution=)]
    2015-12-26 hixiaoluo

    好文章,值得看。

    0

  9. [GetPortalCommentsPageByObjectIdResponse(id=1835608, encodeId=eafb1835608a9, content=<a href='/topic/show?id=cfdc22e893f' target=_blank style='color:#2F92EE;'>#临床应用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22789, encryptionId=cfdc22e893f, topicName=临床应用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fc8528, createdName=clmlylxy, createdTime=Sat Sep 03 03:59:00 CST 2016, time=2016-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=55232, encodeId=b742552328c, content=谢谢分享,, beContent=null, objectType=article, channel=null, level=null, likeNumber=172, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Sat Jan 09 22:52:00 CST 2016, time=2016-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=55233, encodeId=c6fc5523379, content=已经收藏!, beContent=null, objectType=article, channel=null, level=null, likeNumber=197, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Sat Jan 09 22:52:00 CST 2016, time=2016-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=55229, encodeId=9c135522984, content=好,, beContent=null, objectType=article, channel=null, level=null, likeNumber=169, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Sat Jan 09 22:51:00 CST 2016, time=2016-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=55230, encodeId=684b55230e3, content=赞一个,, beContent=null, objectType=article, channel=null, level=null, likeNumber=133, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Sat Jan 09 22:51:00 CST 2016, time=2016-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=55231, encodeId=414f5523183, content=赞!, beContent=null, objectType=article, channel=null, level=null, likeNumber=195, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Sat Jan 09 22:51:00 CST 2016, time=2016-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=48354, encodeId=3ebf4835400, content=好文章,值得看。, beContent=null, objectType=article, channel=null, level=null, likeNumber=132, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bc301610909, createdName=hixiaoluo, createdTime=Sat Dec 26 16:34:00 CST 2015, time=2015-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=48355, encodeId=b3214835555, content=好文章,值得看。, beContent=null, objectType=article, channel=null, level=null, likeNumber=134, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bc301610909, createdName=hixiaoluo, createdTime=Sat Dec 26 16:34:00 CST 2015, time=2015-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=48356, encodeId=c54f48356a0, content=好文章,值得看。, beContent=null, objectType=article, channel=null, level=null, likeNumber=134, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bc301610909, createdName=hixiaoluo, createdTime=Sat Dec 26 16:34:00 CST 2015, time=2015-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=46687, encodeId=05984668e6a, content=太全面了!非常感谢!, beContent=null, objectType=article, channel=null, level=null, likeNumber=135, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=abdc1672404, createdName=lulu2h, createdTime=Sat Dec 19 00:40:00 CST 2015, time=2015-12-19, status=1, ipAttribution=)]
    2015-12-26 hixiaoluo

    好文章,值得看。

    0

  10. [GetPortalCommentsPageByObjectIdResponse(id=1835608, encodeId=eafb1835608a9, content=<a href='/topic/show?id=cfdc22e893f' target=_blank style='color:#2F92EE;'>#临床应用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22789, encryptionId=cfdc22e893f, topicName=临床应用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fc8528, createdName=clmlylxy, createdTime=Sat Sep 03 03:59:00 CST 2016, time=2016-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=55232, encodeId=b742552328c, content=谢谢分享,, beContent=null, objectType=article, channel=null, level=null, likeNumber=172, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Sat Jan 09 22:52:00 CST 2016, time=2016-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=55233, encodeId=c6fc5523379, content=已经收藏!, beContent=null, objectType=article, channel=null, level=null, likeNumber=197, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Sat Jan 09 22:52:00 CST 2016, time=2016-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=55229, encodeId=9c135522984, content=好,, beContent=null, objectType=article, channel=null, level=null, likeNumber=169, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Sat Jan 09 22:51:00 CST 2016, time=2016-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=55230, encodeId=684b55230e3, content=赞一个,, beContent=null, objectType=article, channel=null, level=null, likeNumber=133, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Sat Jan 09 22:51:00 CST 2016, time=2016-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=55231, encodeId=414f5523183, content=赞!, beContent=null, objectType=article, channel=null, level=null, likeNumber=195, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Sat Jan 09 22:51:00 CST 2016, time=2016-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=48354, encodeId=3ebf4835400, content=好文章,值得看。, beContent=null, objectType=article, channel=null, level=null, likeNumber=132, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bc301610909, createdName=hixiaoluo, createdTime=Sat Dec 26 16:34:00 CST 2015, time=2015-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=48355, encodeId=b3214835555, content=好文章,值得看。, beContent=null, objectType=article, channel=null, level=null, likeNumber=134, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bc301610909, createdName=hixiaoluo, createdTime=Sat Dec 26 16:34:00 CST 2015, time=2015-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=48356, encodeId=c54f48356a0, content=好文章,值得看。, beContent=null, objectType=article, channel=null, level=null, likeNumber=134, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bc301610909, createdName=hixiaoluo, createdTime=Sat Dec 26 16:34:00 CST 2015, time=2015-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=46687, encodeId=05984668e6a, content=太全面了!非常感谢!, beContent=null, objectType=article, channel=null, level=null, likeNumber=135, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=abdc1672404, createdName=lulu2h, createdTime=Sat Dec 19 00:40:00 CST 2015, time=2015-12-19, status=1, ipAttribution=)]
    2015-12-19 lulu2h

    太全面了!非常感谢!

    0

相关资讯

降压药物有助于减轻创伤性脑损伤患者炎症反应

新的研究表明,创伤性脑损伤(TBI)后出现的炎症反应是由肝脏产生的一种蛋白质引起的。研究人员发现,这种蛋白质可以被研发出药物用于治疗高血压。 患者出现创伤性脑损伤(TBI)后,机体各器官系统都会出现明显的炎症反应,尤其是血液系统和肝脏。但是迄今为止医务人员尚未找到这种炎症反应出现的原因和治疗方式。但是乔治敦大学医学中心(GUMC)的最新研究对此有更深的了解,并这有助于为创伤性脑损伤(TBI)患者寻

ESC 2015:午睡有助于降低血压

午睡有助于降低血压减少降压药的使用8月31日ESC会议上来自希腊的研究人员Dr Manolis Kallistratos指出,午睡可降低机体的血压,减少降压药物的使用。 “英国两任颇具影响力的首相——Winston Churchill及Margaret Thatcher,都是午睡的坚定拥护者。而据我们的研究显示,他们可能正是因为有午睡的习惯,所以血压可能较低,使用的降压药物可能因而也较少,” Dr

PLoS Med:高血压(收缩压高)可降低阿尔兹海默症的发病风险

凌乱了,高血压可降低阿尔兹海默症的发病风险?据最新的一项研究表明,存在高血压遗传倾向的个体患阿尔兹海默症的风险较低,但是研究人员表示这种关联可能与降压药物有关而并不是高血压本身可降低阿尔兹海默症的发病风险。 本研究旨在确定阿尔兹海默症可改变的危险因素,研究人员分析了来自阿尔兹海默症遗传联盟和国际阿尔兹海默症基因组项目的数据,包括了研究使用“超级计算机”对每位研究对象的基因组进行分析,寻找单核苷酸多

JAMA Intern Med:收缩压不高的养老院高龄老人降压需慎重

有充分的证据支持:身体素质较好的社区高龄(大于80岁)高血压人群降血压治疗会收益颇多,然而在一些围绕体质虚弱的的老年人观察性研究上,没有显示出降压治疗的优势,甚至出现了降压可能增加患病率、死亡率。 为评估养老院年龄大于80岁的老年人的全因死亡率和收缩压水平以及服用降压药量的关系,研究者开展了这项研究。这项纵向观察研究的观察群体是养老院的高龄老人,研究者分析了低收缩压(<130 mm Hg

降压药依普利酮对慢性肾病有效

日本研究人员在最新临床研究中发现,治疗高血压的药物依普利酮对于因过量摄取盐分而导致的慢性肾脏病也有疗效。今后,在治疗伴随高血压的慢性肾脏病患者时,这种降压药有望成为一个新选择。 慢性肾脏病是各种原因引起的慢性肾脏结构和功能障碍,如未能及时得到有效治疗,将发展成慢性肾功能衰竭,最终形成尿毒症。 东京大学名誉教授藤田敏郎率领的研究小组注意到,糖尿病会给肾脏造成负担,引发肾功能衰竭,而过量摄取盐分,

Diabetologia:睡前服用降压药可降低患糖尿病风险?

本项研究旨在评估睡前服用降压药是否比早上醒来服药能更好的改善血压控制并降低糖尿病风险。研究人员进行了一项前瞻性、随机、非盲法试验,并纳入2012名无糖尿病的高血压患者,其中1,036名为女性,男性976名,平均年龄在52.7±13.6岁。参与者随机分配到并利用计算机生成配置表,分别是在清晨醒来后服用所有降压药物和在睡前服用≥1种降压药物两组。本项研究平均随访5.9年。在随访期间,171名参与者新患